Hims & Hers Health, Inc. (HIMS): A Bull Case Theory

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on wallstreetbets Subreddit Page by MostCapital5741. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc. (HIMS)’s share was trading at $29.46 as of April 15^th. HIMS’s trailing and forward P/E were 55.58 and 49.51 respectively according to Yahoo Finance.

A nurse in a telehealth platform talking with a patient on video call for consultation.

Hims & Hers (HIMS), with a market cap of $6.5B, is emerging as a disruptive force in digital healthcare, delivering staggering growth and redefining patient engagement. For Q1 2025, the company projects 87% to 94% year-over-year revenue growth—up to $540 million—accelerating from 69% in Q4 2024, alongside expected EPS of $0.11. This momentum reflects their direct-to-consumer model, which allows rapid product iteration, data collection, and patient feedback loops that enhance outcomes and fuel further growth. This virtuous cycle of data and AI-driven personalization gives HIMS a strategic edge, potentially leading to a future where AI-powered prescription becomes a reality. In February 2025, HIMS announced its entry into peptide manufacturing—an early move into the GLP-1 trend—with production expected around 2026, positioning them to offer customizable peptide therapies, possibly guided by AI. Concerns about tariffs or macroeconomic headwinds are mitigated by HIMS’ U.S.-based manufacturing and its focus on affordable medications for American consumers. With inelastic demand, cost-saving advantages, and resilient operations, HIMS appears not just insulated from volatility but positioned to thrive in it. As investors seek growth and defensibility, HIMS stands out with a flywheel model, a visionary management team, and exposure to massive long-term tailwinds in healthcare and AI.

Hims & Hers Health, Inc. (HIMS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 38 hedge fund portfolios held HIMS at the end of the fourth quarter which was 31 in the previous quarter. While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than HIMS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article was originally published at Insider Monkey.